Company / Cash & Equivalents
Neurocrine Biosciences Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$713.0M
FY2025
5-year range
$233.0M / $713.0M
FY2021-FY2025
Trend
+206.0%
vs FY2024
Sector context
#29 of 209
Health Care
What the data says
Cash & Equivalents changed +206% YoY in FY2025, a notable deviation from the 9-year average annual change of +51%.
Based on SEC 10-K filings.
$713M in FY2025 with a 5-year CAGR of +30.7%. Top quartile in the Health Care sector.
Improved from $251M to $713M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +39.5%
- 5-Year CAGR
- +30.7%
- 10-Year CAGR
- -
Sector benchmark
Top 14% in Health CareTop 14% of 209This company $713.0M Sector average $696.0M
▼
+2.4% above sector average
Key checks
Key Insights
- 5-year CAGR of +30.7%, indicating consistent growth.
- In FY2025, cash & equivalents increased 206.0% year-over-year.
- Ranks #29 out of 209 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2016.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $713.0M | +206.0% |
| FY2024 | $233.0M | -7.2% |
| FY2023 | $251.1M | -4.5% |
| FY2022 | $262.9M | -22.9% |
| FY2021 | $340.8M | +82.1% |
| FY2020 | $187.1M | +66.6% |
| FY2019 | $112.3M | -20.8% |
| FY2018 | $141.7M | -44.4% |
| FY2017 | $254.7M | +205.9% |
| FY2016 | $83.3M | +12.2% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026